SMARCA2/4 PROTAC for Targeted Protein Degradation and Cancer Therapy

ADVERTISEMENT RETURN TO ISSUEPREVPatent HighlightNEXTSMARCA2/4 PROTAC for Targeted Protein Degradation and Cancer TherapyRobert B. Kargbo*Robert B. KargboUsona Institute, 277 Granada Drive, San Luis Obispo, California 93401-7337, United States*Email: [email protected]More by Robert B. Kargbohttp://orcid.org/0000-0002-5539-6343Cite this: ACS Med. Chem. Lett. 2020, 11, 10, 1797–1798Publication Date (Web):July 16, 2020Publication History Received20 June 2020Published online16 July 2020Published inissue 8 October 2020https://pubs.acs.org/doi/10.1021/acsmedchemlett.0c00347https://doi.org/10.1021/acsmedchemlett.0c00347editorialACS PublicationsCopyright © 2020 American Chemical Society. This publication is available under these Terms of Use. Request reuse permissions This publication is free to access through this site. Learn MoreArticle Views10730Altmetric-Citations9LEARN ABOUT THESE METRICSArticle Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated. Share Add toView InAdd Full Text with ReferenceAdd Description ExportRISCitationCitation and abstractCitation and referencesMore Options Share onFacebookTwitterWechatLinked InRedditEmail PDF (698 KB) Get e-AlertscloseSUBJECTS:Assays,Cancer,Cells,Degradation,Genetics Get e-Alerts